The price of Avidity Biosciences Inc. (NASDAQ: RNA) closed at $11.70 in the last session, down -3.15% from day before closing price of $12.08. In other words, the price has decreased by -$0.38 from its previous closing price. On the day, 1058266 shares were traded. RNA stock price reached its highest trading level at $12.53 during the session, while it also had its lowest trading level at $11.68.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
Ratios:
We take a closer look at RNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 12.40 and its Current Ratio is at 12.40. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 15 when LEVIN ARTHUR A sold 100 shares for $22.01 per share. The transaction valued at 2,201 led to the insider holds 19,330 shares of the business.
LEVIN ARTHUR A sold 10,000 shares of RNA for $236,567 on Feb 14. The Chief Scientific Officer now owns 19,330 shares after completing the transaction at $23.66 per share. On Feb 03, another insider, Boyce Sarah, who serves as the President and CEO of the company, sold 3,221 shares for $24.26 each. As a result, the insider received 78,141 and left with 53,352 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 785.32M and an Enterprise Value of 209.12M. For the stock, the TTM Price-to-Sale (P/S) ratio is 84.40 while its Price-to-Book (P/B) ratio in mrq is 1.47. Its current Enterprise Value per Revenue stands at 21.64 whereas that against EBITDA is -1.07.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $25.74, while it has fallen to a 52-week low of $9.83. The 50-Day Moving Average of the stock is 15.13, while the 200-Day Moving Average is calculated to be 17.89.
Shares Statistics:
According to the various share statistics, RNA traded on average about 1.37M shares per day over the past 3-months and 1.02M shares per day over the past 10 days. A total of 70.43M shares are outstanding, with a floating share count of 50.87M. Insiders hold about 5.17% of the company’s shares, while institutions hold 99.00% stake in the company. Shares short for RNA as of Apr 27, 2023 were 9.93M with a Short Ratio of 9.93M, compared to 10.91M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 14.02% and a Short% of Float of 14.20%.
Earnings Estimates
The company has Moderna, Inc. analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $1.52, with high estimates of $31.35 and low estimates of $30.77.
EPS for the following year is $Stocks, with Stocks analysts recommending between $Stocks and $ETF.
